Pierre Tambourin
Directeur Général chez Société d'Economie Mixte Genopole SAEM
Profil
Pierre Tambourin is currently the Chief Executive Officer of Société d'Economie Mixte Genopole SAEM and the Chairman-Strategic Board of BioRéalités SAS.
He was previously the Chief Executive Officer of Genopole Entreprises (Private Equity).
Postes actifs de Pierre Tambourin
| Sociétés | Poste | Début |
|---|---|---|
BioRéalités SAS
 BioRéalités SAS Pharmaceuticals: MajorHealth Technology BioRéalités develops novel therapeutic and diagnostic tools to improve the life of colorectal cancer patients. The company was created as an SAS in february 2007, and has been furthering the work of its founders in the field of oncology, with a particular focus on the characterization of a novel target for colorectal cancer therapy. BioRéalités currently employs 13 staff and recently moved in their own facility, which include a 200 m2 laboratory area. The company has been granted an exclusive international license to exploit a PCT patent lodged by INSERM, CNRS, and the University of Montpellier 1 in 2006. | Président | 03/05/2010 |
Société d'Economie Mixte Genopole SAEM
 Société d'Economie Mixte Genopole SAEM Real Estate DevelopmentFinance Société d'Economie Mixte Genopole SAEM engages in the development of biotechnologies. It specializes in the research of genomics and genetics. The company was founded in 1998 and is headquartered in Evry, France. | Directeur Général | - |
Anciens postes connus de Pierre Tambourin
| Sociétés | Poste | Fin |
|---|---|---|
Genopole Entreprises (Private Equity)
 Genopole Entreprises (Private Equity) Investment ManagersFinance Genopole Entreprises is the investment division of the French incubation platform Genopole®, which is specialized in genomics and post-genomics, and regroups teaching and research laboratories as well as startup incubation facilities and biotechnology companies. Genopole was founded by regional government entities. Genopole Entreprises is based in Evry on the south side of Paris and manages the G1J-Genopole 1er Jour Ile-de-France regional pre-seed fund (Genopole 1st Day), established in 1999. The firm aims to identify potential biotechnology entrepreneurs within public and private research laboratories. They invest public funds as well as a majority of private capital, both domestic and international. Investors include large corporations, regional government entities, financial institutions and private equity firms. They cooperate with Cap Décisif Management SAS, a Paris-based regional venture capital firm with a generalist approach. | Directeur Général | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Genopole Entreprises (Private Equity)
Genopole Entreprises (Private Equity) Investment ManagersFinance Genopole Entreprises is the investment division of the French incubation platform Genopole®, which is specialized in genomics and post-genomics, and regroups teaching and research laboratories as well as startup incubation facilities and biotechnology companies. Genopole was founded by regional government entities. Genopole Entreprises is based in Evry on the south side of Paris and manages the G1J-Genopole 1er Jour Ile-de-France regional pre-seed fund (Genopole 1st Day), established in 1999. The firm aims to identify potential biotechnology entrepreneurs within public and private research laboratories. They invest public funds as well as a majority of private capital, both domestic and international. Investors include large corporations, regional government entities, financial institutions and private equity firms. They cooperate with Cap Décisif Management SAS, a Paris-based regional venture capital firm with a generalist approach. | Finance |
BioRéalités SAS
BioRéalités SAS Pharmaceuticals: MajorHealth Technology BioRéalités develops novel therapeutic and diagnostic tools to improve the life of colorectal cancer patients. The company was created as an SAS in february 2007, and has been furthering the work of its founders in the field of oncology, with a particular focus on the characterization of a novel target for colorectal cancer therapy. BioRéalités currently employs 13 staff and recently moved in their own facility, which include a 200 m2 laboratory area. The company has been granted an exclusive international license to exploit a PCT patent lodged by INSERM, CNRS, and the University of Montpellier 1 in 2006. | Health Technology |
Société d'Economie Mixte Genopole SAEM
Société d'Economie Mixte Genopole SAEM Real Estate DevelopmentFinance Société d'Economie Mixte Genopole SAEM engages in the development of biotechnologies. It specializes in the research of genomics and genetics. The company was founded in 1998 and is headquartered in Evry, France. | Finance |
